PRESS RELEASE: June is Cancer Survivors Month: AscellaHealth Helps Improve Outcomes, Lower Costs with High-Touch Specialty Pharmacy Solutions
Advocating on behalf of cancer survivors on June 4, 2019, National Cancer Survivors Day
BERWYN, Pa.–(BUSINESS WIRE) — AscellaHealth a specialty-focused pharmaceutical management company serving commercial, Medicare and Medicaid segments, supports June as National Cancer Survivor Month and June 4, 2019, National Cancer Survivors Day, by acknowledging the ongoing challenges of cancer survivorship. AscellaHealth’ clinical and educational programs can play a key role in assisting members with their prescribed therapy, beginning with diagnosis, to reduce high deductible/co-insurance costs through financial assistance programs and by partnering with physicians and pharmacists.
“Cancer survivorship begins on the day of diagnosis, and thanks to earlier detection there has been continued increase in survival rates, fueling our commitment to helping health plan members battle cancer in a way that improves quality of life and maximizes benefit plans,” says Dea Belazi, president and CEO, AscellaHealth. “The cancer pipeline is ripe with innovative therapeutic options, with emerging combinations of medicines holding particular promise for cancer patients. These patients require a strategic approach to specialty pharmacy that is designed to improve outcomes and care coordination. AscellaHealth’s high-touch model includes clinical interventions, adherence counseling, psychosocial assessment, integrated nursing staff, refill reminders and delivery coordination as part of AscellaHealth’s innovative specialty pharmacy strategy.”
The most recent figures show an estimated 15.5 million cancer survivors in the United States, which is expected to increase to 20.3 million by 2026.
AscellaHealth’s program includes specialty drug management, formulary management services/rebates, competitive pricing and innovative discounting, drug utilization review, case management services/therapy management, clinical review/prior authorization, pharmacy and therapeutic management committee, flexible claims adjudication system, drug information and news reporting.
Belazi concludes, “By reducing costs, including discounted prices as part of the exceptional value we provide, our approach to specialty drugs can be a vital factor for members living with cancer.”
About AscellaHealth
AscellaHealth, a national PBM serving commercial, Medicare and Medicaid segments offers high quality prescription drug management services along with other customizable services, such as carved-out specialty pharmacy services and cost-savings discount programs through its unique and proprietary service that extends discounts on prescription medications to customers more than any other PBM in the industry. Visit www.ascellahealth.com.
Contacts
Media:
CPR Communications
201.641.1911 x 54
###
China Can Weaponize Prescription Drugs To Hit US In Trade War, Says Expert
By Nandika Chand
ibtimes.com – The United States’ heavy reliance on China for prescription drugs is becoming a national security concern. The concern is that China could weaponize its drugs industry to squeeze the United States, much like its media and officials have threatened to do with rare earth minerals, as both countries face-off in an increasingly fraught trade war.
China has a plan to restrict the export of rare earths to the U.S. if the trade war gets deeper, Bloomberg reported recently. These minerals are vital for the electronics industry and for making artificial magnets, which have many industrial uses
To view the original article in its entirety, please click here.
Polio: Statement of the Twenty-first IHR Emergency Committee
By Kimberly Leonard
Who.int – The twenty-first meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) regarding the international spread of poliovirus was convened by the Director-General on 14 May 2019 at WHO headquarters with members, advisers and invited Member States attending via teleconference, supported by the WHO secretariat.
The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV). The Secretariat presented a report of progress for affected IHR States Parties subject to Temporary Recommendations. The following IHR States Parties provided an update on the current situation and the implementation of the WHO Temporary Recommendations since the Committee last met on 19 February 2019: Afghanistan, DR Congo, Indonesia, Nigeria, Pakistan and Somalia.
To view the original article in its entirety, please click here.